Twenty years after Next Generation Sequencing (NGS) transformed the landscape of genomics, its role in biopharmaceutical development is undergoing a pivotal shift. Once viewed as an exploratory tool, NGS is now emerging as a robust, regulatory-endorsed method for ensuring viral safety in biological medicinal products.
In this webinar, we trace the evolution of NGS from its early experimental applications to its growing acceptance as a standard in quality and safety testing. We’ll explore the scientific, operational, and regulatory hurdles that have historically limited adoption—and how recent advances in technology, validation frameworks, and industry collaboration are helping to overcome them. Whether you're in strategy, quality, regulatory affairs, or technical development, this session will help you understand how NGS is reshaping the future of viral safety.
Key Learning Objectives
- Key drivers accelerating regulatory acceptance and standardization
- Case studies and lessons learned from early adopters
- Strategic implications for manufacturers of biologics and advanced therapies
